Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Abelson

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|April 25, 2008
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingMark B Abelson, Paul J Gomes
The Ocular Surface|November 1, 2006
Ocular allergic disease: mechanisms, disease sub-types, treatmentMark B Abelson, Lisa Smith, Matthew Chapin
Current Opinion in Ophthalmology|April 29, 2009
Dry eye in 2008Mark B Abelson, George W Ousler, Ciera Maffei
Current Allergy and Asthma Reports|March 26, 2011
Antihistamines in ocular allergy: are they all created equal?Mark B Abelson, James T McLaughlin, Paul J Gomes
Clinical Therapeutics|August 12, 2008
Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitisGail L Torkildsen, Mark B Abelson, Paul J Gomes
Clinical Therapeutics|August 30, 2003
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tearsMark B Abelson, Steven Pratt, Joseph E Mussoline, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 15, 2005
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissueRudolph S Wagner, Mark B Abelson, Aron Shapiro, et al.
Ophthalmology and Therapy|September 29, 2017
Use of the Controlled Adverse Environment (CAE) in Clinical Research: A ReviewGeorge W Ousler, David Rimmer, Lisa M Smith, et al.
The Ocular Surface|November 30, 2006
Methodologies for the study of ocular surface diseaseGeorge W Ousler, Paulo J Gomes, Donna Welch, et al.
Clinical Therapeutics|September 27, 2003
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge modelsDennis L Spangler, Mark B Abelson, Andrew Ober, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Expert Opinion on Drug Metabolism & Toxicology|April 25, 2008
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingMark B Abelson, Paul J Gomes
The Ocular Surface|November 1, 2006
Ocular allergic disease: mechanisms, disease sub-types, treatmentMark B Abelson, Lisa Smith, Matthew Chapin
Current Opinion in Ophthalmology|April 29, 2009
Dry eye in 2008Mark B Abelson, George W Ousler, Ciera Maffei
Current Allergy and Asthma Reports|March 26, 2011
Antihistamines in ocular allergy: are they all created equal?Mark B Abelson, James T McLaughlin, Paul J Gomes
Clinical Therapeutics|August 12, 2008
Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitisGail L Torkildsen, Mark B Abelson, Paul J Gomes
Clinical Therapeutics|August 30, 2003
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tearsMark B Abelson, Steven Pratt, Joseph E Mussoline, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 15, 2005
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissueRudolph S Wagner, Mark B Abelson, Aron Shapiro, et al.
Ophthalmology and Therapy|September 29, 2017
Use of the Controlled Adverse Environment (CAE) in Clinical Research: A ReviewGeorge W Ousler, David Rimmer, Lisa M Smith, et al.
The Ocular Surface|November 30, 2006
Methodologies for the study of ocular surface diseaseGeorge W Ousler, Paulo J Gomes, Donna Welch, et al.
Clinical Therapeutics|September 27, 2003
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge modelsDennis L Spangler, Mark B Abelson, Andrew Ober, et al.
Pageof 7